PRQR Jul 2024 2.500 call
| Previous close | 0.1200 |
| Open | 0.1500 |
| Bid | 0.0000 |
| Ask | 0.0500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1200 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 672 |
GlobeNewswireProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Massachusetts. As part of the conference program, Gerard Platenburg, Chief Scientific Officer and Co-Founder, ProQR Therapeutics, will present on June 20, 2024 at 2:00pm ET: “Developing Axiomer RNA Editing Techno
Simply Wall St.Shareholders in ProQR Therapeutics (NASDAQ:PRQR) are in the red if they invested five years ago
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic...
- GlobeNewswire
ProQR Announces First Quarter 2024 Operating and Financial Results
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General Meeting scheduled for May 22, 2024Continued strength of leading IP estate around ADAR-mediated RNA editing highlighted with successful defense of challenge to granted patent in Europe€102.7 million as of end of Q1 providing runway into mid
